Codexis stock analysis
Codexis (4QK) Stock Price & Analysis
4QK Stock Chart & Stats
- Day’s Range
- EUR 0.94 - EUR 1.04
- 52-Week Range
- EUR 0.82 - EUR 2.45
- Previous Close
- EUR 1.03
- Volume
- N/A
- Average Volume (3M)
- 120
- Market Cap
- EUR 105.69M
- Enterprise Value
- EUR 148.70M
- Total Cash (Recent Filing)
- EUR 72.66M
- Total Debt (Recent Filing)
- EUR 72.27M
- Price to Earnings (P/E)
- ―
- Beta
- 0.93
- Next Earnings
- Feb 25, 2027 (Est.)
- EPS Estimate
- -0.07
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Product Growth
Strong recent revenue and product-sales growth indicates improving commercial traction across Codexis’s pharma biocatalysis business. Continued adoption of proprietary enzymes can expand recurring supply opportunities, strengthen customer relationships, and support a more durable revenue base.
ECO Synthesis Platform Progress
Progress in scale, cycle time, and product purity strengthens the technical case for ECO Synthesis as a commercially viable platform. These improvements can support larger customer programs, improve process economics, and increase the likelihood of adoption in future oligonucleotide manufacturing.
Improving Gross Margins
High and improving product gross margins demonstrate attractive economics for Codexis’s enzyme offerings and suggest that commercial growth need not require proportionate cost increases. Sustained margins could provide greater operating leverage as revenue expands and expenses scale more efficiently.
Bears Say
Persistent Net Losses
Codexis remains loss-making even after a substantial year-over-year improvement, showing that strong gross margins have not yet translated into sustainable earnings. Continued losses could constrain reinvestment capacity and leave the business dependent on operating improvements or external financing.
Elevated Leverage
The sharp increase in leverage reduces financial flexibility while Codexis is still reporting losses and negative cash flow. Higher debt obligations can absorb future cash resources, restrict capital allocation, and increase the company’s exposure to financing and covenant requirements.
Scale-Up And Commercial Timing Risk
Codexis has demonstrated meaningful technical progress, but larger-scale readiness and commercial deployment remain unfinished. Delays in process optimization, regulatory work, or customer negotiations could postpone revenue conversion and extend the period before platform investments generate significant returns.
Codexis News
4QK FAQ
What was Codexis’s price range in the past 12 months?
What is Codexis’s market cap?
When is Codexis’s upcoming earnings report date?
How were Codexis’s earnings last quarter?
Is Codexis overvalued?
Does Codexis pay dividends?
What is Codexis’s EPS estimate?
How many shares outstanding does Codexis have?
What happened to Codexis’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Codexis?
What is the TipRanks Smart Score and how is it calculated?
Codexis Stock Smart Score
Company Description
Codexis
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Alison Moore
- Employees
- 146
- Website
- www.codexis.com
- Address
- 200 Penobscot Drive, Redwood City, CA, 94063, US
Codexis (4QK) Earnings & Revenues
4QK Earnings Call
Earnings Call SentimentPositive
The call was strongly positive overall. Highlights included substantial revenue growth, improving gross margins, lower operating expenses, improved biocatalysis product sales, progress to 100-gram ECO Synthesis scale, three to fourfold higher potency in stereocontrolled siRNA, growing customer and CDMO engagement, and a cash runway expected through 2028. The main negatives were the continuing net loss, a lower cash balance versus year-end 2025, the remaining work required to reach larger-scale manufacturing, and uncertain timing for additional commercial agreements.
View all DE:4QK earnings summaries4QK Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 3 | 14 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 0 | 0 | 12 |












